Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-25-013522
Filing Date
2025-03-18
Accepted
2025-03-18 17:09:05
Documents
1
Period of Report
2025-03-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1742332139.html 4  
1 FORM 4 wk-form4_1742332139.xml 4 5335
  Complete submission text file 0001628280-25-013522.txt   6751
Mailing Address 1207 17TH AVENUE SUITE 103 NASHVILLE TN 37212
Business Address
KAZIMI A J (Reporting) CIK: 0001075050 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 25749440

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)